Amendment 4 to Collaboration AgreementAmendment 4 to Collaboration Agreement • August 6th, 2020 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations
This Amendment 4 to the Collaboration Agreement (the “Amendment 4”) is effective as of December 15, 2019 (the “Amendment 4 Effective Date”) and amends that certain Collaboration Agreement between The University of Texas M.D. Anderson Cancer Center (“MD Anderson”) and Oncternal Therapeutics, Inc., formerly Tokalas, Inc. (“Oncternal”) effective as of December 15, 2014 (the “Agreement”), as amended by Amendment 1 effective as of January 24, 2016 (the “Amendment 1”), by Amendment 2 effective as of May 1, 2016 (the “Amendment 2”), and by Amendment 3 effective as of September 17, 2018 (“Amendment 3”). Oncternal and MD Anderson are sometimes referred to collectively herein as the “Parties” or individually as a “Party.”
